Axsome Therapeutics (AXSM) Enterprise Value (2015 - 2026)
Axsome Therapeutics (AXSM) reported Enterprise Value of -$305.1 million for Q1 2026, down 1.4% on a YoY basis from -$309.4 million in Q1 2025, and up 5.52% sequentially from -$322.9 million in Q4 2025.
Axsome Therapeutics (AXSM) Enterprise Value (2015 - 2026) Analysis & Trends
Axsome Therapeutics (AXSM) has 12 years of Enterprise Value data on file, last reported at -$305.1 million in Q1 2026.
- For the quarter ending Q1 2026, Enterprise Value fell 1.4% year-over-year to -$305.1 million; the trailing twelve-month figure through Mar 2026 stood at -$305.1 million (down 1.4% YoY), and the FY2025 full-year result was -$322.9 million, down 2.4% from the prior year.
- Enterprise Value climbed to -$305.1 million in Q1 2026, from -$322.9 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$73.4 million in Q2 2022 to a low of -$437.1 million in Q2 2023.
- A 5-year average of -$289.4 million and a median of -$315.4 million in 2024 frame the typical range for Enterprise Value.
- Across the five-year window, Enterprise Value surged 48.57% in 2022 and slumped 495.57% in 2023, its largest moves.
- Tracing AXSM's Enterprise Value over 5 years: stood at -$200.8 million in 2022, then slumped by 92.29% to -$386.2 million in 2023, then grew by 18.34% to -$315.4 million in 2024, then slipped by 2.4% to -$322.9 million in 2025, then climbed by 5.52% to -$305.1 million in 2026.
- Business Quant data shows AXSM's Enterprise Value at -$305.1 million in Q1 2026, -$322.9 million in Q4 2025, and -$325.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,079.99 Bn | 66,079.71 Bn | - | -283.54 Mn |
| 2 | Nanobiotix | 1,912.79 Bn | 1,912.73 Bn | - | -61.40 Mn |
| 3 | Akari Therapeutics | 1,022.34 Bn | 1,022.34 Bn | - | -2.83 Mn |
| 4 | BeOne Medicines | 471.68 Bn | 466.89 Bn | 1.35 Bn | -4.79 Bn |
| 5 | Vertex Pharmaceuticals | 122.31 Bn | 115.06 Bn | 2.59 Bn | -7.25 Bn |
| 6 | Regeneron Pharmaceuticals | 70.24 Bn | 61.49 Bn | 3.31 Bn | -8.75 Bn |
| 7 | Belite Bio | 63.01 Bn | 63.01 Bn | - | - |
| 8 | Argenx Se | 56.02 Bn | 50.83 Bn | 1.41 Bn | -5.18 Bn |
| 9 | Alnylam Pharmaceuticals | 37.46 Bn | 34.45 Bn | 959.66 Mn | -3.01 Bn |
| 10 | Axsome Therapeutics | 12.31 Bn | 12.01 Bn | 176.48 Mn | -305.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -305.10 Mn |
| Dec 31, 2025 | -322.93 Mn |
| Sep 30, 2025 | -325.27 Mn |
| Jun 30, 2025 | -303.00 Mn |
| Mar 31, 2025 | -300.90 Mn |
| Dec 31, 2024 | -315.35 Mn |
| Sep 30, 2024 | -327.34 Mn |
| Jun 30, 2024 | -315.66 Mn |
| Mar 31, 2024 | -331.40 Mn |
| Dec 31, 2023 | -386.19 Mn |
| Sep 30, 2023 | -416.56 Mn |
| Jun 30, 2023 | -437.11 Mn |
| Mar 31, 2023 | -246.52 Mn |
| Dec 31, 2022 | -200.84 Mn |
| Sep 30, 2022 | -227.50 Mn |
| Jun 30, 2022 | -73.39 Mn |
| Mar 31, 2022 | -84.70 Mn |
| Dec 31, 2021 | -86.47 Mn |
| Sep 30, 2021 | -114.62 Mn |
| Jun 30, 2021 | -141.20 Mn |